.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Teva
Cantor Fitzgerald
Healthtrust
Fish and Richardson
Moodys
Cerilliant
Federal Trade Commission
Chubb

Generated: June 27, 2017

DrugPatentWatch Database Preview

ORAPRED ODT Drug Profile

« Back to Dashboard

Which patents cover Orapred Odt, and when can generic versions of Orapred Odt launch?

Orapred Odt is a drug marketed by Concordia Pharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nine patent family members in seven countries.

The generic ingredient in ORAPRED ODT is prednisolone sodium phosphate. There are eighty-five drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for Tradename: ORAPRED ODT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list52
Clinical Trials: see list60
Patent Applications: see list6,696
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ORAPRED ODT at DailyMed

Pharmacology for Tradename: ORAPRED ODT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006ABRXYesNo6,740,341► SubscribeY ► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006ABRXYesNo6,740,341► SubscribeY ► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006ABRXYesYes6,740,341► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ORAPRED ODT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 20065,178,878► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 20065,178,878► Subscribe
Concordia Pharms Inc
ORAPRED ODT
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 20065,178,878► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ORAPRED ODT

Country Document Number Estimated Expiration
Hong Kong1146901► Subscribe
Australia1922000► Subscribe
Australia753476► Subscribe
Japan2002530322► Subscribe
European Patent Office2260836► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Merck
Healthtrust
Moodys
McKinsey
Harvard Business School
Medtronic
Cipla
Fish and Richardson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot